A phase II trial of FLX 787 in patients with multiple sclerosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Nov 2017
At a glance
- Drugs FLX 787 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 28 Nov 2017 Status changed from recruiting to active, no longer recruiting, according to a Flex Pharma media release.
- 02 Aug 2017 According to a Flex Pharma media release, the company expects important data readouts from this study in 2018.
- 15 Jun 2016 Planned number of patients changed to 50, according to Flex Pharma media release.